2 Deoxy D Ribose may promote hair growth and aid wound healing, potentially enhancing microneedling effects. Users discuss its combination with microneedling for better hair growth results.
Mixing RU58841 with cetosomal minoxidil is discussed due to scalp irritation from ethanol PG vehicles. A mixture of the two turned bright pink when left to dry.
Finasteride and minoxidil are recommended for hair loss, with skepticism about additional treatments like electro stimulation and oxygen infusion, which are seen as ineffective and costly. Pulsed ultrasound may enhance drug delivery, but most other treatments are considered ineffective.
The post and conversation are about skepticism towards a new hair loss treatment containing 2-deoxy-D-ribose, copper peptides, and exosomes, with concerns about the legitimacy of the product and its website. The treatment's effectiveness and authenticity are questioned due to lack of testing and transparency.
Minoxidil may inhibit collagen synthesis at high concentrations, with anecdotal reports of skin aging but limited research. Dermatologists and other specialists show little interest in studying minoxidil's side effects.
Koshine KX-826 has different versions, and the green version uses a plant-based carrier that may be less irritating for those sensitive to propylene glycol. Users report irritation with some versions of KX-826.
People are humorously discussing unconventional and satirical uses of minoxidil, such as drinking it or injecting it, and the potential absurd consequences. The conversation also touches on the ineffectiveness and risks of these methods compared to proper topical application with microneedling.
The conversation is about starting a Discord group for people using KX-826 as their only treatment for hair loss, excluding those who are not serious or use multiple treatments. Someone agrees with the idea but mentions "GP :3," which is unclear.
The conversation is about treatments for androgenetic alopecia, focusing on hyperresponders. Treatments include Minoxidil, finasteride, RU58841, leg training, and cold therapy.
The post discusses a hair loss treatment regime using Nizoral, a laser helmet, dermaroller, bentonite clay mask with essential oils, and ketoconazole shampoo. The user avoids finasteride and minoxidil due to concerns about side effects and pet safety.
Store minoxidil and minoxidil+finasteride solutions in a cool environment, ideally below 25°C, to maintain effectiveness. Consider using a wine cellar or fridge for stable, low temperatures.
PP405 is anticipated as a future treatment for dormant hair follicles, but its effectiveness and safety are uncertain. Current treatments include oral minoxidil and microneedling, with some avoiding finasteride due to side effects.
The conversation humorously acknowledges the role of mice in testing Minoxidil for hair loss while also discussing the ethics of animal testing. Some users argue against animal testing, citing cruelty, while others defend its necessity for medical advancements.
The conversation discusses DIY cosmetic procedures like PRP, mesotherapy, and micro-needling, with some users experimenting with Minoxidil, finasteride, and RU58841 for hair loss. It highlights a community of mostly older women performing these treatments themselves.
The method combines finasteride, minoxidil, intense leg exercises, and cold exposure to treat androgenetic alopecia. It aims to boost metabolism and reduce androgenic effects, enhancing hair growth.
Orient Bio is developing a PLGA formulated version of Cyclosporine A to stimulate hair growth without its immunosuppressant effects. Users discuss various treatments like Clascoterone, PP405, minoxidil, and tacrolimus, expressing hope for new developments and sharing personal experiences with these treatments.
The conversation discusses concerns about oral minoxidil potentially aging the face by affecting collagen, questioning its systemic effects. The user has successfully used topical minoxidil for years and is hesitant to switch to oral minoxidil.
The conversation is about the effectiveness of Minoxidil formulations with different alcohol and propylene glycol (pg) ratios. The user finds that a formulation with 20% pg and 80% ethanol dries faster but is concerned about absorption time.
The user is currently using 0.025% Pantostin but plans to switch to 0.1% Alfatradiol. They will also use high-dose Kx826, high-dose Minoxidil, and aggressive microneedling for hair regrowth.
The user "Dekar__" is experiencing a significant shed on Minoxidil 5% foam after 2.5 months of use, with no visible regrowth yet. They are also using Alfatradiol.
PP405 targets hair follicle stem cells differently than exercise-induced lactate, suggesting exercise alone may not replicate its benefits. Minoxidil and finasteride are recommended alongside exercise for hair regrowth, with additional suggestions like spicy food and infrared exposure.
The conversation humorously suggests that drug use might be more effective for hair retention than traditional treatments like minoxidil or finasteride. It attributes full heads of hair in homeless individuals to lifestyle factors like reduced stress or hormonal changes.
A user humorously suggested smoking minoxidil in a blunt as an alternative hair growth method, sparking a satirical discussion on unconventional and unsafe ways to use minoxidil. The conversation included various suggestions like oral pills, rectal administration, and other absurd methods, with some users warning against the dangers of such practices.
Intense microneedling with heavy pressure and bleeding did not improve hair growth after 4 months. The user advises against this method, noting no benefits and potential harm, and mentions using minoxidil without success.
High cost of studying 3α-Hydroxysteroid dehydrogenase in hair loss led to suggestions of crowdfunding for research. Users discussed using Procyanidin B2/melatonin topical treatment and tracking funds with blockchain.
The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.